Pure MHC is a platform technology company with expertise in disease-specific target identification and validation for use in immunotherapeutic drug development for cancer, infectious and autoimmune disease. This proprietary technology provides access to every protein that is either synthesized or degraded inside any particular cell, including proteins that are not expressed on the cell surface, and consistently identifies previously unidentified disease targets and those targets previously known or suggested to be associated with the disease state. This analysis is undertaken without bias toward or against any protein under investigation. Pure MHC’s key enabling technology, Soluble HLA (sHLA), allows for the expression of a pure source of HLA in a diseased cell of choice. Using sensitive mass spectroscopy techniques referred to as Deep Ligand Sequencing, Pure MHC compares thousands of peptides recovered from HLA complexes extracted from cancer, infected, and normal cells and then determines with high confidence which peptides are unique, and therefore represent novel disease targets, to the affected cell line or primary tissue. Biomarkers discovered by Pure MHC represent nature’s own means of marking diseased cells for elimination, and Pure MHC has developed a unique class of monoclonal antibodies that are specific for the biomarkers that the company discovers and validates. These highly specific monoclonal antibodies mimic the immune system’s recognition mechanisms, and the provision of these monoclonal reagents compliments the discovery of disease-specific biomarkers. Moreover, Pure MHC’s monoclonal antibodies, referred to as T Cell Receptor mimics (TCRm), can readily be optimized to treat disease, for use in diagnostics or for other pre-clinical development assays. To learn more about Pure MHC, visit www.puremhc.com or contact info@puremhc.com.